Top 5 Rheumatoid Arthritis treatment startups in USA
Jun 24, 2026
|
Like
26
1
Funding: $637M
Nimbus Therapeutics develops highly selective and potent small molecule drugs aimed at suppressing known factors that cause serious diseases, including metabolic diseases, cancer, and immune-inflammatory disorders (psoriasis, arthritis). The company's drug discovery platform utilizes advanced protein structure analysis, molecular modeling, machine learning-based prediction, and comprehensive data analysis within a target-oriented approach. The atomic-level data obtained using these tools enables the creation of highly accurate molecules that determine optimal pharmacological profiles for the treatment of disease pathology.
Nimbus Therapeutics develops highly selective and potent small molecule drugs aimed at suppressing known factors that cause serious diseases, including metabolic diseases, cancer, and immune-inflammatory disorders (psoriasis, arthritis). The company's drug discovery platform utilizes advanced protein structure analysis, molecular modeling, machine learning-based prediction, and comprehensive data analysis within a target-oriented approach. The atomic-level data obtained using these tools enables the creation of highly accurate molecules that determine optimal pharmacological profiles for the treatment of disease pathology.
2
Funding: $558M
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing inflammatory-disease-focused therapies.
3
Funding: $496.4M
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
4
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
5
Funding: $327.6M
AltruBio develops antibody-targeted therapies for psoriatic arthritis and ulcerative colitis
AltruBio develops antibody-targeted therapies for psoriatic arthritis and ulcerative colitis
★
See also:
